NASDAQ:CLLS Cellectis Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cellectis SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.85 +0.50 (+2.88 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$17.26Now: $17.85▼$17.8650-Day Range$15.96MA: $18.01▼$20.8452-Week Range$7.32Now: $17.85▼$21.97Volume94,184 shsAverage Volume168,345 shsMarket Capitalization$758.02 millionP/E RatioN/ADividend YieldN/ABeta2.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.83, Cellectis has a forecasted upside of 95.1% from its current price of $17.85.Amount of Analyst CoverageCellectis has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesCellectis has received 376 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCellectis has received 265 “underperform” votes. (Add your “underperform” vote.)Community SentimentCellectis has received 58.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote “Outperform” if you believe CLLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 16.41% of the stock of Cellectis is held by insiders.Percentage Held by InstitutionsOnly 32.74% of the stock of Cellectis is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cellectis are expected to decrease in the coming year, from ($1.31) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -11.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -11.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLLS Previous Symbol CUSIPN/A CIK1627281 Webwww.cellectis.com Phone33-1-81-69-16-00Debt Debt-to-Equity Ratio0.02 Current Ratio6.56 Quick Ratio6.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.99 million Price / Sales32.97 Cash FlowN/A Price / Cash FlowN/A Book Value$8.37 per share Price / Book2.13Profitability EPS (Most Recent Fiscal Year)($2.41) Net Income$-102,090,000.00 Net Margins-89.50% Return on Equity-18.00% Return on Assets-13.83%Miscellaneous Employees161 Outstanding Shares42,466,000Market Cap$758.02 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $17.85 +0.50 (+2.88 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CLLS News and Ratings via Email Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Cellectis (NASDAQ:CLLS) Frequently Asked Questions How has Cellectis' stock price been impacted by COVID-19 (Coronavirus)? Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLLS stock has increased by 56.2% and is now trading at $17.85. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cellectis? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis. When is Cellectis' next earnings date? Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Cellectis. How were Cellectis' earnings last quarter? Cellectis SA (NASDAQ:CLLS) posted its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.03. The biotechnology company had revenue of $4.62 million for the quarter, compared to analyst estimates of $2.37 million. Cellectis had a negative return on equity of 18.00% and a negative net margin of 89.50%. View Cellectis' earnings history. What price target have analysts set for CLLS? 7 brokerages have issued 1-year target prices for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' share price to reach $34.83 in the next year. This suggests a possible upside of 95.1% from the stock's current price. View analysts' price targets for Cellectis. Are investors shorting Cellectis? Cellectis saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 540,900 shares, an increase of 18.4% from the August 15th total of 456,800 shares. Based on an average daily trading volume, of 170,500 shares, the short-interest ratio is currently 3.2 days. Approximately 1.3% of the company's stock are short sold. View Cellectis' Short Interest. Who are some of Cellectis' key competitors? Some companies that are related to Cellectis include Legend Biotech (PCVX), Kodiak Sciences (KOD), Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), Mesoblast (MESO), Forma Therapeutics (FMTX), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY), Editas Medicine (EDIT), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Intel (INTC), Micron Technology (MU), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP) and Sorrento Therapeutics (SRNE). Who are Cellectis' key executives? Cellectis' management team includes the following people: Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)Mr. Eric Dutang, Chief Financial Officer (Age 45)Ms. Elsy Boglioli, Chief Operating Officer (Age 37)Mr. Jean Charles Epinat, Chief Technological Officer When did Cellectis IPO? (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. What is Cellectis' stock symbol? Cellectis trades on the NASDAQ under the ticker symbol "CLLS." Who are Cellectis' major shareholders? Cellectis' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (2.53%), Sumitomo Mitsui Trust Holdings Inc. (1.73%), Prosight Management LP (0.65%), Hudson Bay Capital Management LP (0.38%), New York State Common Retirement Fund (0.25%) and Vident Investment Advisory LLC (0.20%). Which major investors are selling Cellectis stock? CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sumitomo Mitsui Trust Holdings Inc., Bank of America Corp DE, Hudson Bay Capital Management LP, UBS Group AG, WS Management Lllp, Vident Investment Advisory LLC, and Vident Investment Advisory LLC. Which major investors are buying Cellectis stock? CLLS stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Ikarian Capital LLC, Marshall Wace LLP, Marshall Wace North America L.P., RMB Capital Management LLC, Exchange Traded Concepts LLC, Princeton Capital Management LLC, and Two Sigma Advisers LP. How do I buy shares of Cellectis? Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cellectis' stock price today? One share of CLLS stock can currently be purchased for approximately $17.85. How big of a company is Cellectis? Cellectis has a market capitalization of $758.02 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe. What is Cellectis' official website? The official website for Cellectis is www.cellectis.com. How can I contact Cellectis? Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected] This page was last updated on 9/27/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
